Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through NeuroSense Therapeutics’ biotech disclosures can feel like decoding a lab notebook. Clinical trial updates, burn-rate projections, and patent notes sprawl across hundreds of pages, making it hard to spot what matters before the next ALS data milestone. Stock Titan solves this problem by turning every new NeuroSense Therapeutics SEC filing into an easy-to-read brief the moment it hits EDGAR.
Need the NeuroSense Therapeutics quarterly earnings report 10-Q filing to compare R&D spend, or the latest 8-K material events explained after a PrimeC trial update? Our platform delivers AI-powered summaries, red-flag highlights, and side-by-side comparisons. Get NeuroSense Therapeutics insider trading Form 4 transactions and Form 4 insider transactions real-time so you can monitor when executives adjust their holdings ahead of key readouts. You’ll also find the NeuroSense Therapeutics annual report 10-K simplified, complete with context on pipeline progress, cash runway, and intellectual-property status—all without reading every footnote.
Whether you’re tracking NeuroSense Therapeutics earnings report filing analysis, checking a proxy statement executive compensation section, or simply understanding NeuroSense Therapeutics SEC documents with AI, Stock Titan keeps you ahead. Investors use our real-time alerts to follow NeuroSense Therapeutics executive stock transactions Form 4, gauge dilution risk from S-3 shelves, and see how fresh capital supports the multicenter PARADIGM trial. Every filing type—10-K, 10-Q, 8-K, S-1, DEF 14A—is indexed, timestamped, and translated into plain language, so you spend time making decisions, not parsing biotech jargon.
NeuroSense Therapeutics Ltd. (NRSN) filed an S-8 registering securities for an employee benefit plan and incorporated prior public filings and its Form 8-A description. The filing outlines the companys indemnification and insurance framework for officers and directors, specifying circumstances where indemnity and insurance are permitted and where they are excluded, and includes undertakings to update the registration statement with required prospectus information, material changes to distribution plans, and to remove unsold securities at offering termination.
NeuroSense Therapeutics amended its prospectus supplement to update the maximum amount of ordinary shares it may sell through a Capital on Demand™ Sales Agreement with JonesTrading. The company may offer and sell ordinary shares having an aggregate offering price of up to $14,203,914, which does not include approximately $2.8 million of shares previously sold under the same agreement. Sales may be made as at-the-market offerings under Rule 415, and JonesTrading will act as sales agent but is not required to sell any specific number of shares.
The filing notes a Public Float of $50,961,630, based on 20,466,518 ordinary shares held by non-affiliates and a closing price of $2.49 used for that calculation. Because the Public Float is under $75.0 million, the company is limited by Form F-3 General Instruction I.B.5 to selling no more than one-third of that value in any 12-month period; during the last 12 months it sold about $2.8 million under this rule. The document reiterates that investing involves a high degree of risk and refers investors to the Risk Factors in the prospectus materials.
NeuroSense Therapeutics Ltd. (NRSN) filed a Form 6-K detailing the outcome of its pre-New Drug Submission (pre-NDS) meeting with Health Canada concerning PrimeC, the company’s investigational therapy for amyotrophic lateral sclerosis (ALS). The regulator discussed use of the Notice of Compliance with Conditions (NOC/c) expedited pathway, which could shorten the review timeline if eligibility is granted.
The parties are finalizing official minutes; a formal notice will confirm whether NeuroSense can proceed with an NDS under the NOC/c route. Management described the dialogue as constructive and positive but disclosed no definitive decision, review timetable, or financial metrics.
A comprehensive forward-looking statements section highlights risks including potential rejection or delay by Health Canada, funding requirements, Phase 3 timing, market-size uncertainties, and the company’s ability to remain listed on Nasdaq. No earnings data or new operational figures were provided.
FAQ
What is the current stock price of Neurosense Therapeutics (NRSN)?
What is the market cap of Neurosense Therapeutics (NRSN)?
